MD Anderson Research Highlights for December 6, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Clinical advances include positive data with targeted therapies for HER2 exon 20 mutant lung cancer, for older patients with mantle cell lymphoma and for BRAFV600E-mutant gliomas. Additional discoveries include insights into chromosomal...
Antihistamines can influence immunotherapy response by enhancing T cell activation
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication...
MD Anderson Research Highlights: SITC 2021 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into basic, translational and clinical cancer research...
MD Anderson and Schrödinger announce strategic research collaboration to accelerate development of WEE1 program
The University of Texas MD Anderson Cancer Center and Schrödinger, Inc. today announced a two-year strategic research collaboration focused on accelerating and optimizing the development of Schrödinger’s WEE1 inhibitor program, an investigational therapeutic approach designed to target the WEE1 kinase.
The collaboration brings together the translational research and drug development expertise of MD Anderson’s Therapeutics...
MD Anderson and the Rare Cancer Research Foundation launch collaboration to accelerate the development of treatments for rare cancers
The University of Texas MD Anderson Cancer Center and the Rare Cancer Research Foundation today announced the launch of a collaboration designed...
MD Anderson and Siemens Healthineers collaborating to enable consistent clinical implementation of quantitative MRI
The University of Texas MD Anderson Cancer Center and Siemens Healthineers today announced the collaborative development of a global education...
MD Anderson and BostonGene announce strategic alliance to advance personalized cancer diagnostics and treatments
The University of Texas MD Anderson Cancer Center and BostonGene Corporation today announced a strategic alliance to advance the development...
MD Anderson celebrates World Cancer Research Day, progress made to end cancer through research
The University of Texas MD Anderson Cancer Center is proud to support World Cancer Research Day, Sept. 24, and its efforts to promote cancer...
MD Anderson Research Highlights: ESMO 2021 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and...
Link between inflammation and pancreatic cancer development uncovered
HOUSTON ― A new discovery from researchers at The University of Texas MD Anderson Cancer Center has clarified the long-established connection...
MD Anderson and SNIPR BIOME collaborate to advance next-generation CRISPR microbiome therapeutics
The University of Texas MD Anderson Cancer Center and SNIPR BIOME today announced a strategic collaboration to advance new CRISPR-based microbiome...
MD Anderson and Bellicum announce additional license agreement for use of CaspaCIDe® safety switch
The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals, Inc. today announced a global option and license agreement...
MD Anderson statement regarding third dose of COVID-19 vaccine for immunocompromised patients
A multidisciplinary group of oncology and infectious disease experts at The University of Texas MD Anderson Cancer Center have reviewed all...
MD Anderson and Blueprint Medicines announce strategic collaboration to accelerate BLU-222 development
The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation today announced a three-year strategic research collaboration...
MD Anderson and Hummingbird Bioscience announce strategic research collaboration to advance innovative immunotherapies
The University of Texas MD Anderson Cancer Center and Hummingbird Bioscience today announced the launch of a multi-year strategic research...
Engineered NK cells can eliminate glioblastoma stem cells
Preclinical research from The University of Texas MD Anderson Cancer Center finds that although glioblastoma stem cells (GSCs) can be targeted...
Glioblastoma study discovers protective role of metabolic enzyme, revealing a novel therapeutic target
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel function for the metabolic enzyme medium-chain acyl-CoA...
New AI-based tool can find rare cell populations in large single-cell datasets
Researchers at The University of Texas MD Anderson Cancer Center have developed a first-of-its-kind artificial intelligence (AI)-based tool...
Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients with advanced cancers
ABSTRACT #3001
The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center...
MD Anderson and Refuge Biotechnologies collaborate to advance next-generation cell therapies for treatment of solid tumors
The University of Texas MD Anderson Cancer Center and Refuge Biotechnologies, Inc. today announced a strategic collaboration to advance new...
NK cells with bispecific antibody show activity against lymphoma cells
Cytokine-activated natural killer (NK) cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody...
Mitochondrial enzyme found to block cell death pathway points to new cancer treatment strategy
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) plays an important and previously unknown role in blocking a form of cell death...
MD Anderson and Broad Institute launch new translational research platform focused on rare cancers
The University of Texas MD Anderson Cancer Center and the Broad Institute of MIT and Harvard today announced the launch of a new translational...
Single-cell map of early stage lung cancer and normal lung sheds light on tumor development, new therapeutic targets
Researchers at The University of Texas MD Anderson Cancer Center have developed a first-of-its-kind spatial atlas of early-stage lung cancer...
Antiviral T cells safe and effective for treating debilitating complication common after stem cell transplants
A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy...
MD Anderson and Boehringer Ingelheim expand collaboration to advance lung cancer therapies
The University of Texas MD Anderson Cancer Center and Boehringer Ingelheim today announced the extension and expansion of their joint Virtual...
Researchers identify surface protein as a new osteosarcoma therapeutic target for antibody-drug conjugates
Abstract #LB008
A preclinical study led by researchers at The University of Texas MD Anderson Cancer Center shows an antibody-drug...
Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis
ABSTRACT #2417
Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most...
MD Anderson and TriSalus Life Sciences announce strategic research collaboration to evaluate treatment of solid tumors
The University of Texas MD Anderson Cancer Center and TriSalus Life Sciences today announced a strategic research collaboration to evaluate...
MD Anderson’s Guillermina Lozano elected to Fellows of the AACR Academy
Guillermina (Gigi) Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected...
New sequencing approach finds triple-negative breast cancers continue accumulating genetic changes during tumor growth
Overcoming previous technical challenges with single-cell DNA (scDNA) sequencing, a group led by researchers at The University of Texas MD...
Study finds high tumor mutation burden predicts immunotherapy response in some, but not all, cancers
A high rate of genetic mutations within a tumor, known as high tumor mutation burden (TMB), was only useful for predicting clinical responses...
MD Anderson, Orionis launch Project Helios to advance new cancer medicines
The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division and Orionis Biosciences today announced the launch of...
Collagen plays protective role during pancreatic cancer development
Contrary to long-held beliefs, Type I collagen produced by cancer-associated fibroblasts may not promote cancer development but instead plays...
Break Through Cancer launches collaborative model with MD Anderson, top U.S. research institutions in pursuit of cancer cures
Break Through Cancer today announced its formal launch as a public foundation designed to find new solutions to the most intractable challenges...
MD Anderson and Mirati Therapeutics announce KRAS strategic research and development collaboration in solid tumors
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development...
Legendary MD Anderson faculty member Dr. Emil J Freireich passes away at 93
Emil J Freireich, M.D., a trailblazing oncologist who developed groundbreaking therapies for childhood leukemia and came to be recognized...
New computational tool reliably differentiates between cancer and normal cells from single-cell RNA-sequencing data
In an effort to address a major challenge when analyzing large single-cell RNA-sequencing datasets, researchers from The University of Texas...
MD Anderson and UroGen Pharma announce strategic research collaboration to advance investigational treatment for high-grade bladder cancer
The University of Texas MD Anderson Cancer Center and UroGen Pharma Ltd. today announced a strategic three-year collaboration agreement to...
MD Anderson and Xencor enter strategic collaboration to develop novel T cell-engaging bispecific antibodies for potential treatment of patients with cancer
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization...
Single-cell analysis of metastatic gastric cancer finds diverse tumor cell populations associated with patient outcomes
Researchers from The University of Texas MD Anderson Cancer Center who profiled more than 45,000 individual cells from patients with peritoneal...
Immunology study finds protein critical to T cell metabolism and anti-tumor immune response
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a protein called NF-kappa B-inducing kinase (NIK) is...